Novartis reported 2025 sales of $54.5 billion as Amarin revenue fell 6.5%

Novartis reported 2025 sales of $54.5 billion, up 8% year over year, while earnings per share rose 15% to $8.98. Amarin reported that for fiscal 2025, total revenue declined 6.5% year over year to $213.6 million, as generic versions of Vascepa have been available for years.

Amarin has an approved product on the market, Vascepa, a medication designed to reduce cardiovascular event risks. The company said it narrowed its net loss per share from $0.20 in 2024 to $0.09 in 2025 through workforce reductions and other cost-cutting measures.

Amarin is also engaged in a legal battle with Hikma Pharmaceuticals, alleging that Hikma marketed its generic version of Vascepa in ways that infringe on a still-patented use of the original medicine. The case has reached the U.S. Supreme Court.

The company partnered with Recordati to market Vascepa in 59 countries, primarily in Europe, receiving a $25 million upfront payment with potential milestone payments of up to $150 million.

Novartis said its product portfolio spans numerous therapeutic areas and that newer products are already materially impacting financial results. Its blockbuster heart failure medication Entresto lost patent protection last year, yet the company still expects slight sales growth in 2026.

The company said Fabhalta, a treatment for two rare disorders first approved in December 2023, generated $505 million in revenue in 2025, a 291% year-over-year increase. Novartis also said it has increased its payout every year since 1996.